

Cabrini Research – Consumer story

Mr Paul Mercer

For Paul Mercer, Cabrini was a natural choice for care, given it was home to both his treatment team and a promising Phase III clinical trial investigating a new protocol that combined different therapies for CLL. When his haematologist flagged the trial as an option, Mr Mercer was eager to participate and make a difference, well aware that, “a tablet-only treatment protocol has been a goal of the community for some time.”

Since enrolling in the trial, Mr Mercer’s experience has been overwhelmingly positive, confirming Cabrini’s reputation for professionalism and excellence. “I cannot thank enough the staff at Cabrini who supported me during my treatment” he notes, adding how “I received nothing but the best of care from my doctor, nurses, and the trials team,” in particular Demis Balamatsias, his trial coordinator.

Reflecting on his participation, Mr Mercer expressed gratitude for having been able to access and contribute towards improved treatment modalities for CLL.



Demis Balamatsias (left) played a critical role as trial coordinator during Paul Mercer's (right) participation in a Phase III clinical trial.

“I feel lucky to have been given the opportunity... I have a few months to go before completing treatment and with the improvements I have experienced, I am looking forward to resuming a more healthy and active life.”

Looking ahead, Mr Mercer remains committed to staying informed about new therapeutic developments for his condition, understanding the critical importance of clinical trials in meeting the needs of future patients. “The active involvement of patients and caregivers can only support this and should be encouraged – the development of more effective treatments with longer remission periods is a vision we can all buy into.”